A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an ...

Moderna’s stock has taken a big hit that might signal the end of this year’s cancer vaccine-driven rally. It may not, however ...

If it does turn again, the question is how much more the stock could lose on top of this drop: in past market-wide downturns, ...

So, right now, is Moderna a buy on the dip? It's important to keep in mind that the stock still has climbed more than 500% ...

Moderna and Merck are expected to share the Phase 3 data for their experimental cancer vaccine this weekend at a medical ...

Moderna stock fell an average of 31.4% across the seven market shocks since its first trading day in December 2018, compared ...

Already trending higher since late 2025, Moderna shares skyrocketed in August. This super rally came on the heels of the company's unveiling of positive late-stage clinical trial data for Intismeran ...

Moderna (MRNA) stock wavered Monday on more muted expectations for its Merck (MRK)-partnered cancer vaccine following ...